Lower relapses rate with infliximab versus adalimumab in sight threatening uveitis: a multicenter study of 330 patients.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of ophthalmology"
DOI: 10.1016/j.ajo.2022.02.002
Abstract: OBJECTIVE To compare relapse rate of sight threatening non infectious uveitis (NIU) in patients treated with infliximab (IFX) or adalimumab (ADA). DESIGN Observational retrospective multicenter study. SUBJECTS 330 patients (median age of 36 years (IQR… read more here.
Keywords: 330 patients; rate; multicenter study; relapse rate ... See more keywords